Remove 2019 Remove Licensing Remove Packaging
article thumbnail

Setting up Sitecore Content Serialization using Sitecore for Visual Studio (SVS) – GUI

Perficient: Drug Development

SVS is designed to work with a command line in the background and also provides an interactive interface in Visual Studio 2019. SVS requires a license; we can utilize the same license as Sitecore TDS. If you don’t have a license, then you can purchase from the TDS site.

article thumbnail

European Commission vs Big Pharma, or profit vs access?  

Drug Discovery World

The commission is proposing the introduction of temporary emergency marketing authorisations 1. Extra foreign inspections Since July 2019, the MRA (Mutual Recognition Agreement) between the EU and the US FDA has been fully in force.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Steep FY2025 PDUFA Fee Increase: Ways to Reduce the Full Fee Rate for Repurposed Drugs

The Premier Consulting Blog

As outlined in the table below, application fee rates, such as for a New Drug Application (NDA) or Biologics License Application (BLA), will increase by almost $300,000 in FY2025 (effective October 1, 2024). October 2019. [iv] July 28, 2023. iii] US Food and Drug Administration. Guidance for Industry. Website: [link].

article thumbnail

Noema Pharma raises CHF54 million in Series A financing round led by Sofinnova Partners and Polaris Partners

The Pharma Data

I n-licensing of four clinical-stage product candidates to treat orphan neurological disorders. Sofinnova Partners seed-financed Noema in 2019. Sofinnova Partners seed-financed Noema in 2019. A 2019 seed investment from Sofinnova Partners formed Noema. BASEL, Switzerland, Dec.

article thumbnail

FDA Accepts for Review Pfizer’s Supplemental Application for ABRILADA™ (adalimumab-afzb) Interchangeability

The Pharma Data

Food and Drug Administration (FDA) has accepted for review the Prior Approval Supplement (PAS) to the Biologics License Application (BLA) for ABRILADA™ (adalimumab-afzb) as an interchangeable biosimilar to Humira® (adalimumab). Pfizer Inc. NYSE: PFE) today announced that the U.S.

article thumbnail

Article EMA Thank You EMA’s 2023 new medicines report suggests return to pre-pandemic volume

Agency IQ

When compared to the year immediately prior to the pandemic, however, 2023 actually marks an increase in volume, with only 70 opinions issued in 2019. This approval type has always been uncommon – before the pandemic, this pathway was used just eight times between 2015 and 2019. [ for the years 2020 to 2022. Based on the E.U.

article thumbnail

Regeneron Reports Third Quarter 2020 Financial and Operating Results

The Pharma Data

billion versus third quarter 2019 (4). billion versus third quarter 2019. billion versus third quarter 2019. Total revenues increased by 32% to $2.294 billion in the third quarter of 2020, compared to $1.744 billion in the third quarter of 2019. TARRYTOWN, N.Y. , Third quarter 2020 EYLEA ® U.S. Total revenues (4). $.